Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial

European Urology

Volumn 67, Issue 2, 2015, Pages 223-230

  Saad, Fred ^a   De Bono, Johann ^b   Shore, Neal ^c   Fizazi, Karim ^d   Loriot, Yohann ^d   Hirmand, Mohammad ^e   Franks, Billy ^f   Haas, Gabriel P ^f   Scher, Howard I ^g  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Carolina Urologic Research Center   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Medivation Inc   (United States)

^f Astellas Global Medical Affairs   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

AFFIRM trial; Androgen receptor inhibitor; Enzalutamide; Metastatic castration resistant prostate cancer; Prostate specific antigen

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; ENZALUTAMIDE; LACTATE DEHYDROGENASE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PHENYLTHIOHYDANTOIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG EFFICACY; GLEASON SCORE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; TREATMENT DURATION; ANALOGS AND DERIVATIVES; AUSTRALIA; BLOOD; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; EUROPE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NORTH AMERICA; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SOUTH AFRICA; SOUTH AMERICA; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; AUSTRALIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EUROPE; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NORTH AMERICA; PHENYLTHIOHYDANTOIN; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTORS; SOUTH AFRICA; SOUTH AMERICA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84920666284     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.08.025     Document Type: Article

References (26)

1. R.B. Montgomery, E.A. Mostaghel, and R. Vessella Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447 4454
2. C. Massard, and K. Fizazi Targeting continued androgen receptor signaling in prostate cancer Clin Cancer Res 17 2011 3876 3883
3. H.I. Scher, and C.L. Sawyers Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis J Clin Oncol 23 2005 8253 8261
4. C. Tran, S. Ouk, and N.J. Clegg Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
5. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
6. T.A. Stamey, N. Yang, A.R. Hay, J.E. McNeal, F.S. Freiha, and E. Redwine Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909 916
7. G.F. Carvalhal, S.N. Daudi, and D. Kan Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes Urology 76 2010 1072 1076
8. S. Halabi, C.Y. Lin, and W.K. Kelly Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer J Clin Oncol 32 2014 671 677
9. R.B. Shah, R. Mehra, and A.M. Chinnaiyan Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program Cancer Res 64 2004 9209 9216
10. M.M. Oken, R.H. Creech, and D.C. Tormey Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
11. C.S. Cleeland, and K.M. Ryan Pain assessment: global use of the Brief Pain Inventory Ann Acad Med Singapore 23 1994 129 138
12. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
13. T.M. Beer, A.J. Armstrong, and D.E. Rathkopf Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433
14. A. Zivi, C. Massard, and J. De-Bono Changing therapeutic paradigms in castrate-resistant prostate cancer Clin Genitourin Cancer 8 2010 17 22
15. K. Miller, P.-A. Abrahamsson, K. Akakura, F.M.J. Debruyne, C.P. Evans, and L. Klotz The continuing role of PSA in the detection and management of prostate cancer Eur Urol Suppl 6 2007 327 333
16. T.A. Stamey, M. Caldwell, J.E. McNeal, R. Nolley, M. Hemenez, and J. Downs The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172 2004 1297 1301
17. W.D. Figg, K. Ammerman, and N. Patronas Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer Cancer Invest 14 1996 513 517
18. S.L. Turner, S. Gruenewald, N. Spry, and V. Gebski Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer Br J Cancer 84 2001 297 302
19. A.J. Armstrong, E. Garrett-Mayer, and Y.C. Ou Yang Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer J Clin Oncol 25 2007 3965 3970
20. A. Italiano, C. Ortholan, and S. Oudard Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer Eur Urol 55 2009 1368 1376
21. K. Fizazi, H.I. Scher, and A. Molina Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
22. E.D. Kwon, C.G. Drake, and H.I. Scher Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Lancet Oncol 15 2014 700 712
23. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
24. P.F. Schellhammer, G. Chodak, J.B. Whitmore, R. Sims, M.W. Frohlich, and P.W. Kantoff Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial Urology 81 2013 1297 1302
25. R.J. Lee, P.J. Saylor, and M.D. Michaelson A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases Clin Cancer Res 19 2013 3088 3094
26. D.C. Smith, M.R. Smith, and C. Sweeney Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial J Clin Oncol 31 2013 412 419